GLP-1 Pipeline Tracker for Weight Loss Drugs
Only 5 of the 79 drugs on this list hold an FDA approval for weight management. Look up any of the others by name, company or class to see the stage it has reached and the last step we could confirm.
Go to what each status means, the seven drug classes or FAQs
Find a drug
Data as of November 19, 2026
- Approved 13
- Submitted 10
- Phase 3 19
- Phase 2 18
- Phase 1 7
- Discontinued 12
Showing 79 drugs
This view leaves out discontinued drugs.
Nothing matches that search. Try a shorter name, or switch off a filter.
| Drug | Status | Class | Company | Route | What we confirmed |
|---|---|---|---|---|---|
| GLP-1 RA 22 listed | |||||
| Albiglutide Tanzeum | Discontinued | GLP-1 RA | GSK | Injection, weekly | The FDA drug database shows Tanzeum, a diabetes drug, as discontinued. Its label last changed in December 2017. Source, Albiglutide |
| Beinaglutide | Approved | GLP-1 RA | Shanghai Benemae | Injection, three times daily | Benemae announced its Chinese registration certificate for weight loss on July 28, 2023. Source, Beinaglutide |
| Berobenatide PF-08653944; MET-097i | Phase 3 | GLP-1 RA | Pfizer | Injection, weekly or monthly | In Phase 3 on Pfizer’s November 3, 2026 pipeline. Thirteen Phase 3 trials are registered, the first from December 2025. Source, Berobenatide |
| Bofanglutide GZR18 | Submitted | GLP-1 RA | Gan & Lee Pharmaceuticals | Injection, every two weeks | China’s drug regulator took the weight management application for review on September 2, 2026. Source, Bofanglutide |
| Dulaglutide Trulicity | Approved | GLP-1 RA | Eli Lilly | Injection, weekly | The FDA cleared Trulicity for type 2 diabetes on September 18, 2014. It has no weight loss approval. Source, Dulaglutide |
| Ecnoglutide XW003 | Approved | GLP-1 RA | Sciwind Biosciences | Injection, weekly | Sciwind announced Chinese approval for chronic weight management in adults on March 6, 2026. Source, Ecnoglutide |
| Efpeglenatide | Approved | GLP-1 RA | Hanmi Pharmaceutical | Injection, weekly | South Korea’s drug ministry licensed it as an obesity treatment on October 7, 2026. Source, Efpeglenatide |
| Efsubaglutide alfa supaglutide | Approved | GLP-1 RA | Innogen | Injection, weekly | Sold in China for type 2 diabetes. Its obesity trial finished main follow-up in July 2026, with results due by year end. Source, Efsubaglutide alfa |
| Exenatide Byetta; Bydureon | Discontinued | GLP-1 RA | AstraZeneca | Injection, twice daily or weekly | Byetta, Bydureon and Bydureon BCise each show as discontinued in the FDA drug database. Source, Exenatide |
| HDM1702 semaglutide injection (Huadong) | Submitted | GLP-1 RA | Huadong Medicine | Injection, weekly | Huadong’s own version of semaglutide. China took its weight management application for review on April 14, 2026. Source, HDM1702 |
| Liraglutide Victoza; Saxenda | Approved | GLP-1 RA | Novo Nordisk | Injection, daily | The FDA cleared Saxenda for weight management on December 23, 2014. Victoza, for diabetes, dates from January 2010. Source, Liraglutide |
| Lixisenatide Adlyxin; Lyxumia | Discontinued | GLP-1 RA | Sanofi | Injection, daily | The European Commission withdrew the Lyxumia license on December 18, 2025, at Sanofi’s request. Source, Lixisenatide |
| Loxenatide PEG-loxenatide; PEX168 | Approved | GLP-1 RA | Jiangsu Hansoh | Injection, weekly | Cleared in China on May 5, 2019, for type 2 diabetes only. Source, Loxenatide |
| MET-224o PF-08656796 | Discontinued | GLP-1 RA | Pfizer | Oral | Dropped during Phase 1, according to the pipeline Pfizer published on August 4, 2026. Source, MET-224o |
| Noiiglutide SHR20004 | Phase 2 | GLP-1 RA | Jiangsu Hengrui | Injection | The obesity Phase 2 record has had no update since March 2022. A separate Phase 3 diabetes trial is finished. Source, Noiiglutide |
| SAL0150 | Phase 1 | GLP-1 RA | Shenzhen Salubris | Oral, weekly or every two weeks | A peptide tablet cleared for human trials in China in March 2026. A Phase 2 diabetes trial is registered but not open. Source, SAL0150 |
| Semaglutide Ozempic; Wegovy | Approved | GLP-1 RA | Novo Nordisk | Injection, weekly | The FDA cleared Wegovy for weight management on June 4, 2021. Ozempic, for type 2 diabetes, dates from December 2017. Source, Semaglutide |
| Semaglutide oral Rybelsus; Wegovy tablets | Approved | GLP-1 RA | Novo Nordisk | Oral, daily | The FDA cleared the Wegovy tablet on December 22, 2025. Rybelsus, the diabetes tablet, dates from September 2019. Source, Semaglutide oral |
| Taspoglutide | Discontinued | GLP-1 RA | Roche | Injection, weekly | Roche handed the drug back to Ipsen in February 2011 after nausea and hypersensitivity problems in trials. Source, Taspoglutide |
| TG103 efmedaglutide alfa | Submitted | GLP-1 RA | CSPC Pharmaceutical | Injection, weekly | China took the weight management application for review on October 13, 2025, and a diabetes application in June 2026. Source, TG103 |
| Visepegenatide PB-119 | Approved | GLP-1 RA | PegBio | Injection, weekly | Cleared in China in November 2025 as a weekly type 2 diabetes drug. It has no weight loss approval. Source, Visepegenatide |
| VRB-101 oral ecnoglutide | Phase 2 | GLP-1 RA | Verdiva Bio | Oral, weekly | One Phase 2b trial is finished. A second was stopped in 2026 as a business decision, not over safety. Source, VRB-101 |
| GLP-1/GIP 11 listed | |||||
| BGM0504 | Submitted | GLP-1/GIP | BrightGene | Injection, weekly | BrightGene said on November 11, 2026 that its Chinese weight loss application, accepted in June, was still in review. Source, BGM0504 |
| Brenipatide LY3537031 | Phase 1 | GLP-1/GIP | Eli Lilly | Injection | A Phase 1 study in people with overweight or obesity is under way. Lilly’s Phase 3 trials test it for alcohol use disorder and for depression. Source, Brenipatide |
| Enicepatide CT-388; RO7795068 | Phase 3 | GLP-1/GIP | Roche | Injection, weekly | Three Phase 3 trials are recruiting. The first opened on March 16, 2026. Source, Enicepatide |
| HDM1005 poterepatide | Phase 3 | GLP-1/GIP | Huadong Medicine | Injection, weekly | Huadong’s 2026 half-year report says the Phase 3 weight management trial has finished enrolling. Source, HDM1005 |
| NNC0519-0130 | Phase 2 | GLP-1/GIP | Novo Nordisk | Injection, weekly | The obesity Phase 2 trial is finished. Novo’s third quarter 2026 investor slides do not mention the drug. Source, NNC0519-0130 |
| Olatorepatide HS-20094 | Submitted | GLP-1/GIP | Hansoh Pharma; Regeneron | Injection, weekly | China took Hansoh’s application for review on June 4, 2026. Regeneron’s first Phase 3 trial is registered but not open. Source, Olatorepatide |
| RAY1225 bilpatide | Phase 3 | GLP-1/GIP | Guangdong Zhongsheng Pharmaceutical | Injection, every two weeks | In October 2026 a 52 week Phase 3 study in China hit its primary target. No application had been filed by then. Source, RAY1225 |
| Ribupatide HRS9531; KAI-9531 | Submitted | GLP-1/GIP | Jiangsu Hengrui; Kailera | Injection, weekly | Hengrui said in July 2026 that the Chinese application accepted in September 2025 was still in review. Source, Ribupatide |
| Tirzepatide Mounjaro; Zepbound | Approved | GLP-1/GIP | Eli Lilly | Injection, weekly | The FDA cleared Zepbound for weight management on November 8, 2023. Mounjaro, for type 2 diabetes, dates from May 2022. Source, Tirzepatide |
| VK2735 | Phase 3 | GLP-1/GIP | Viking Therapeutics | Injection, weekly | Both VANQUISH Phase 3 trials opened in June 2025 and have finished enrolling. Source, VK2735 |
| VK2735 oral | Phase 3 | GLP-1/GIP | Viking Therapeutics | Oral, daily | The two SUNRISE Phase 3 trials of the daily tablet were listed as recruiting on November 16, 2026. Source, VK2735 oral |
| GLP-1/glucagon 6 listed | |||||
| Cotadutide MEDI0382 | Discontinued | GLP-1/glucagon | AstraZeneca | Injection, daily | AstraZeneca reported in April 2023 that it had dropped this daily injection to focus on a weekly drug, AZD9550. Source, Cotadutide |
| DA-1726 | Phase 1 | GLP-1/glucagon | MetaVia; Dong-A ST | Injection, weekly | MetaVia reported 16 week Phase 1 data on November 13, 2026. A Phase 2 liver disease trial is planned for the second half of 2027. Source, DA-1726 |
| Efinopegdutide MK-6024 | Phase 2 | GLP-1/glucagon | Merck & Co. | Injection, weekly | On Merck’s pipeline of November 2, 2026 it sits in Phase 2 for MASH, a liver disease. No obesity trial is open. Source, Efinopegdutide |
| Mazdutide IBI362 | Approved | GLP-1/glucagon | Innovent Biologics | Injection, weekly | Innovent announced Chinese approval for chronic weight management on June 27, 2025. Source, Mazdutide |
| Pemvidutide ALT-801 | Phase 2 | GLP-1/glucagon | Altimmune | Injection, weekly | The obesity Phase 2 trial ended in 2023. Altimmune’s Phase 3 trial is in MASH, a liver disease. Source, Pemvidutide |
| Survodutide BI 456906 | Phase 3 | GLP-1/glucagon | Boehringer Ingelheim | Injection, weekly | After Phase 3 heart safety results on November 9, 2026, the company said it is moving ahead with regulatory submissions. Source, Survodutide |
| GIP/GLP-1/glucagon 4 listed | |||||
| Efocipegtrutide HM15211 | Phase 2 | GIP/GLP-1/glucagon | Hanmi Pharmaceutical | Injection, weekly | Its finished Phase 2 trial was in the liver disease MASH. No obesity trial beyond Phase 1 is registered. Source, Efocipegtrutide |
| MWN101 | Phase 2 | GIP/GLP-1/glucagon | Shanghai Minwei Biotechnology (Lepu Medical) | Injection | Lepu Medical’s 2026 half-year report shows it through Phase 2. A sister drug, MWN109, has entered Phase 3. Source, MWN101 |
| Retatrutide LY3437943 | Phase 3 | GIP/GLP-1/glucagon | Eli Lilly | Injection, weekly | Lilly has reported several positive Phase 3 obesity trials. It aims to send its FDA application in the first three months of 2027. Source, Retatrutide |
| UBT251 | Phase 3 | GIP/GLP-1/glucagon | United Laboratories; Novo Nordisk | Injection, weekly | Chinese Phase 3 testing for obesity started on September 4, 2026. Novo Nordisk runs earlier-stage trials elsewhere. Source, UBT251 |
| Amylin & combos 11 listed | |||||
| ABBV-295 GUB014295 | Phase 2 | Amylin & combos | AbbVie | Injection | AbbVie calls it a long-acting amylin analog. A Phase 2 dose-finding trial opened on August 4, 2026. Source, ABBV-295 |
| ACCG-2671 | Phase 1 | Amylin & combos | Structure Therapeutics | Oral | Structure was running the multiple-dose stage in November 2026 and expects results in the first half of 2027. Source, ACCG-2671 |
| Cagrilintide | Phase 3 | Amylin & combos | Novo Nordisk | Injection, weekly | The RENEW Phase 3 trials of cagrilintide by itself opened on November 5, 2025 and have finished enrolling. Source, Cagrilintide |
| CagriSema cagrilintide + semaglutide | Submitted | Amylin & combos | Novo Nordisk | Injection, weekly | Filed with the FDA in December 2025. On November 14, 2026 Novo still expected a decision before the end of the year. Source, CagriSema |
| Eloralintide LY3841136 | Phase 3 | Amylin & combos | Eli Lilly | Injection, weekly | Shown in Phase 3 for obesity on Lilly’s pipeline dated October 29, 2026. Its first Phase 3 trial opened in December 2025. Source, Eloralintide |
| EloraTZP LY900043; eloralintide + tirzepatide | Phase 3 | Amylin & combos | Eli Lilly | Injection | The first Phase 3 trial of this combined injection opened on October 16, 2026. A second is due to open in December. Source, EloraTZP |
| MET-233i PF-08653945 | Phase 2 | Amylin & combos | Pfizer | Injection, weekly or monthly | In Phase 2 on Pfizer’s November 3, 2026 pipeline, both by itself and combined with berobenatide. Source, MET-233i |
| Petrelintide ZP8396; RO7895515 | Phase 3 | Amylin & combos | Zealand Pharma; Roche | Injection, weekly | Roche opened three Phase 3 trials between September 30 and October 9, 2026, with Zealand as its partner. Source, Petrelintide |
| Pramlintide Symlin | Discontinued | Amylin & combos | AstraZeneca | Injection, at mealtimes | Symlin, cleared in 2005 for people using mealtime insulin, shows as discontinued in the FDA drug database. Source, Pramlintide |
| VRB-103 | Phase 1 | Amylin & combos | Verdiva Bio | Oral, weekly | Its first human study, by itself and with oral ecnoglutide, opened in July 2026 and is recruiting. Source, VRB-103 |
| Zenagamtide amycretin; NNC0487-0111 | Phase 3 | Amylin & combos | Novo Nordisk | Injection, weekly | The AMAZE Phase 3 program opened on February 24, 2026. A Phase 3 trial of a tablet form followed in September. Source, Zenagamtide |
| Oral small molecule 16 listed | |||||
| Aleniglipron GSBR-1290 | Phase 3 | Oral small molecule | Structure Therapeutics | Oral, daily | Two ACCOMPLISH Phase 3 trials are enrolling. Structure expects the first results in the second half of 2028. Source, Aleniglipron |
| ASC30 oral | Phase 3 | Oral small molecule | Ascletis | Oral, daily | Two AURORA Phase 3 trials opened at the end of August 2026 and are recruiting. Source, ASC30 oral |
| Danuglipron PF-06882961 | Discontinued | Oral small molecule | Pfizer | Oral | Pfizer stopped work on April 14, 2025 after one trial participant had a possible drug-related liver injury. Source, Danuglipron |
| Elecoglipron AZD5004; ECC5004 | Phase 3 | Oral small molecule | AstraZeneca | Oral, daily | Nine Phase 3 trials are recruiting. The weight management program opened on June 29, 2026. Source, Elecoglipron |
| HDM1002 conveglipron | Submitted | Oral small molecule | Huadong Medicine | Oral, daily | On November 2, 2026 China agreed to review it as a long-term weight control drug for adults. Source, HDM1002 |
| Lotiglipron PF-07081532 | Discontinued | Oral small molecule | Pfizer | Oral | Pfizer stopped work on June 26, 2023 after raised liver enzymes showed up in early trials. Source, Lotiglipron |
| LY4086940 | Phase 1 | Oral small molecule | Eli Lilly | Oral | Phase 1 is finished. A Phase 2 obesity trial was posted in October 2026 and is not yet recruiting. Source, LY4086940 |
| MDR-001 | Phase 3 | Oral small molecule | MindRank | Oral | MindRank announced the first patient dosed in its Phase 3 trial in China on February 26, 2026. Source, MDR-001 |
| Naperiglipron LY3549492 | Phase 2 | Oral small molecule | Eli Lilly | Oral, daily | Still in Phase 2 on Lilly’s October 29, 2026 pipeline. Two other Phase 2 studies were ended for business reasons. Source, Naperiglipron |
| Orforglipron Foundayo; LY3502970 | Approved | Oral small molecule | Eli Lilly | Oral, daily | The FDA cleared Foundayo for weight management on April 1, 2026. Source, Orforglipron |
| RGT-075 RGT001-075 | Phase 2 | Oral small molecule | Regor Pharmaceuticals | Oral, daily | Both of its Phase 2 obesity trials are finished. The registry entry for the newer one last changed in May 2026. Source, RGT-075 |
| Safiglipron HRS-7535; KAI-7535 | Submitted | Oral small molecule | Jiangsu Hengrui; Kailera | Oral, daily | China took the weight management application for review in early September 2026. Source, Safiglipron |
| TERN-601 | Discontinued | Oral small molecule | Terns Pharmaceuticals (Merck) | Oral, daily | Work ended after liver safety findings in Phase 2. Merck completed its purchase of Terns on May 5, 2026. Source, TERN-601 |
| Tifeglipron CT-996; RO7795081 | Phase 2 | Oral small molecule | Roche | Oral, daily | The Phase 2 obesity trial is finished and a Phase 2 diabetes trial is still recruiting. Nothing in Phase 3 is on the registry. Source, Tifeglipron |
| TQF3250 | Phase 1 | Oral small molecule | Sino Biopharm (Chia Tai Tianqing) | Oral, daily | A 12 week Phase 1b study in people with overweight or obesity opened on September 29, 2026. Source, TQF3250 |
| VCT220 CX11 | Submitted | Oral small molecule | Vincentage Pharma; Corxel | Oral, daily | China’s drug review center lists the application as accepted on July 20, 2026, under number CXHS2600104. Source, VCT220 |
| Other 9 listed | |||||
| Acmopatide CT-868; RO7795074 | Phase 2 | Other | Roche | Injection, daily | Its most recent Phase 2 study, now finished, enrolled adults who have type 1 diabetes plus overweight or obesity. Source, Acmopatide |
| Apitegromab | Phase 2 | Other | Scholar Rock | Injection, IV every 4 weeks | A Phase 2 trial alongside tirzepatide is finished. Its Phase 3 work is in spinal muscular atrophy. Source, Apitegromab |
| Bimagrumab LY3985863 | Phase 2 | Other | Eli Lilly | Injection | An antibody listed in Phase 2 for obesity on Lilly’s October 29, 2026 pipeline. Source, Bimagrumab |
| Dapiglutide ZP7570 | Discontinued | Other | Zealand Pharma | Injection, weekly | Zealand’s pipeline lists this GLP-1 and GLP-2 drug as paused after a Phase 1b trial. Source, Dapiglutide |
| Enobosarm | Phase 2 | Other | Veru | Oral, daily | A Phase 2b trial with semaglutide opened on March 26, 2026 and has finished enrolling. Source, Enobosarm |
| Garetosmab | Phase 2 | Other | Regeneron | Injection | Tested only with trevogrumab and semaglutide, in a Phase 2 trial that is now finished. Source, Garetosmab |
| Maridebart cafraglutide MariTide; AMG 133 | Phase 3 | Other | Amgen | Injection, every 4 weeks | Twelve Phase 3 trials are under way. The first opened on March 12, 2025. Source, Maridebart cafraglutide |
| PF-07976016 | Discontinued | Other | Pfizer | Oral | A GIP receptor blocker. Pfizer’s August 4, 2026 pipeline lists it among programs dropped in Phase 2. Source, PF-07976016 |
| Trevogrumab | Phase 2 | Other | Regeneron | Injection | Its Phase 2 trial, given with semaglutide and in some arms garetosmab, is finished. The record was updated on November 12, 2026. Source, Trevogrumab |
Submitted covers any marketing application that a regulator has agreed to review. Some trackers call this stage Filed. Approved counts an approval in any one country, so read the note to see which country and which use. A drug name opens its ClinicalTrials.gov search in a new tab, and each Source link opens the document we read.
How does the GLP-1 pipeline tracker work?
Each row is one drug, and each drug carries one status: the furthest point it has reached as a weight loss treatment. The list view shows all 79 drugs with the class, the company, how the drug is taken and a one-line note on the last step we could confirm. The by-stage view sets the same drugs out in columns from earliest to latest, so you can count how many sit one step from a decision.
The search box matches a drug name, a brand name, a research code such as LY3437943, a company or a class. The Approved, Oral and Injectable buttons narrow the results, and you can press more than one. The by-stage view adds Phase 1 drugs only after you tick Show Phase 1 drugs, and it never draws discontinued ones. Trial stages come from ClinicalTrials.gov, the U.S. registry of clinical studies, and from company and regulator documents.1
What does each status mean?
The status shows how much testing a drug has passed, not how good the drug is. The FDA describes the three trial phases this way.2
| Status | What is being tested | Typical size and length | What usually happens next |
|---|---|---|---|
| Phase 1 | Safety and dose | Between 20 and 100 volunteers, for several months | About 70% of drugs go on to Phase 2 |
| Phase 2 | Whether the drug works, and its side effects | As many as several hundred patients, for several months to 2 years | About 33% go on to Phase 3 |
| Phase 3 | Benefit in a larger group, with adverse reactions tracked | Between 300 and 3,000 volunteers, for 1 to 4 years | About 25% to 30% go on to the next step |
| Submitted | A regulator is reading the full application | At the FDA, 6 to 10 months once the application is complete3 | Approval or refusal |
| Approved | Nothing further is needed to sell the drug in that country | Not applicable | The note names the country and the approved use |
| Discontinued | Nothing. The company stopped or paused work, or took the product off the market | Not applicable | The drug stays on the list as a record |
Those percentages describe new drugs in general, not weight loss drugs in particular. The plain reading is that most names in the Phase 1 and Phase 2 columns will never reach a pharmacy.
How we chose each status
- The status is for weight management. Where a drug’s late-stage trials are in another disease, the row shows its obesity stage and the note names the rest. Brenipatide has Phase 3 trials in alcohol use disorder and depression, so it appears here at its obesity stage, Phase 1.
- A planned trial does not count. A study that is registered but not yet recruiting does not move a drug up. LY4086940 has a Phase 2 trial on the registry and stays in Phase 1 until that trial opens.
- Approved does not always mean approved for weight loss. Dulaglutide, loxenatide, visepegenatide and efsubaglutide alfa are approved only for type 2 diabetes, and their notes say so.
Phase and timing can change. Companies move trial dates, pause programs and drop drugs with little notice. Each row records what we could confirm on November 19, 2026. It is not a forecast.
What drug classes are in the GLP-1 pipeline?
The 79 drugs fall into seven classes, named for the hormone signals they copy or block. Class labels follow each developer’s own description or its trial record, both linked from the table.
| Class | What the drugs act on | On the list | Examples |
|---|---|---|---|
| GLP-1 RA | The GLP-1 receptor alone. RA is short for receptor agonist | 22 | Semaglutide (Ozempic®, Wegovy®), liraglutide, berobenatide |
| GLP-1/GIP | The GLP-1 and GIP receptors | 11 | Tirzepatide (Mounjaro®, Zepbound®), enicepatide, VK2735 |
| GLP-1/glucagon | The GLP-1 and glucagon receptors | 6 | Survodutide, mazdutide, cotadutide |
| GIP/GLP-1/glucagon | All three receptors, which is why these are called triple agonists | 4 | Retatrutide, UBT251 |
| Amylin and combinations | Amylin receptors, either alone or paired with a GLP-1 drug | 11 | Cagrilintide, CagriSema, eloralintide, petrelintide |
| Oral small molecule | The GLP-1 receptor, using a pill that is not a peptide | 16 | Orforglipron (Foundayo®), aleniglipron, elecoglipron |
| Other | Different targets, including drugs tested alongside a GLP-1 to help keep muscle | 9 | Maridebart cafraglutide, bimagrumab, enobosarm |
Not every pill sits in the Oral small molecule class. Oral semaglutide, VRB-101 and SAL0150 are peptides made into tablets, so they are filed with the GLP-1 RA drugs. Press the Oral button to see all 25 drugs taken by mouth, whatever their class. The other 54 are injections, most of them weekly.
More targets do not make a drug better by default. Only a trial that compares two drugs head to head can show that. For a plain account of how the approved drugs work, see our pages on semaglutide and tirzepatide.
What does the pipeline mean if you want treatment now?
It means very little for a decision you make this year. Nothing in the Phase 1, Phase 2, Phase 3 or Submitted columns can be prescribed in the United States. Investigational drugs are not available by prescription, and the usual way to receive one is to enroll in its clinical trial. The FDA’s expanded access route exists for people with a serious or immediately life-threatening condition and no comparable alternative, which is not how weight loss drugs are normally reached.4
Be careful with websites that sell pipeline drugs. According to the FDA, federal law does not allow retatrutide or cagrilintide in compounding, and neither has been found safe and effective for any condition. It has also warned companies that sold unapproved retatrutide, survodutide and mazdutide labeled “for research purposes” or “not for human consumption.”5
What an AM Rx provider can prescribe today
AM Rx providers are U.S.-licensed, board-certified physicians and nurse practitioners. When one of them finds it appropriate for you, they can prescribe brand-name Zepbound, Wegovy, Mounjaro or Ozempic, or compounded semaglutide or compounded tirzepatide. Mounjaro and Ozempic hold FDA approval for type 2 diabetes only, not for weight loss, so prescribing either one for weight is off-label. No compounded medication is FDA-approved. The FDA does not review compounded drugs for safety, for effectiveness or for quality.
As of November 2026, an AM Rx membership costs $39 in the first month and $135 a month from then on, and medication is billed separately. Our coordination team submits prior authorizations for brand-name medication. If your plan covers the medication, the monthly copay can be as low as $25. Compounded semaglutide costs $199 for a single month, and on a 3-month supply the price starts at $106 a month. Compounded tirzepatide costs $329 for a single month, and on a 3-month supply the price starts at $216 a month.
Two more tools answer the next questions. The GLP-1 supply tracker reports any approved medication that is on the FDA shortage list. The insurance coverage checker walks through how we find out what your plan pays for.
Important safety information for approved GLP-1 medicines. Zepbound and Wegovy carry a boxed warning: they caused thyroid C-cell tumors in rodents, and it is not known whether they do so in people. Do not use them if you or a family member has had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2, known as MEN 2. Serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, severe stomach problems and low blood sugar when taken with insulin or a sulfonylurea. Nausea, diarrhea, vomiting and constipation are among the most common side effects.6,7 In November 2026 the FDA also told makers of GLP-1 drugs to add a warning about NAION, a rare eye condition that can cause sudden vision loss.8 Read the full safety sections for Zepbound and Wegovy.
GLP-1 pipeline tracker FAQs
Which weight loss drugs could the FDA decide on next?
CagriSema is the only drug on this list under FDA review. Novo Nordisk filed it in December 2025 and, on November 14, 2026, still expected a decision before the end of the year.9 Eli Lilly plans to submit retatrutide in the first three months of 2027,10 and Boehringer Ingelheim says it is moving ahead with submissions for survodutide.11 None of these dates is a promise. Reviews can run long, and an application can be refused.
Is retatrutide available by prescription yet?
No. Retatrutide is still in Phase 3 trials and no regulator has approved it, so no pharmacy can fill a prescription for it and AM Rx providers cannot prescribe it. The FDA has stated that federal law does not allow retatrutide in compounding, and it has warned companies that market the drug.5 Lilly plans to ask the FDA for approval early in 2027, and a review takes months after that.3,10
Is there an approved GLP-1 pill for weight loss?
Yes, there are two. The FDA approved Wegovy tablets, an oral form of semaglutide, on December 22, 2025, and Foundayo (orforglipron), a once-daily tablet, on April 1, 2026.12,13 The other 23 oral drugs on this list are in trials, under review outside the United States or discontinued. Press the Oral button in the tracker to see all of them with their current status.
Why does the tracker list approved drugs that U.S. pharmacies do not carry?
Because the Approved label here counts approval by any one country’s regulator, and that is not always the FDA. Seven of the 13 approved drugs on the list have no FDA approval, including mazdutide and ecnoglutide in China and efpeglenatide in South Korea. A provider in the United States cannot prescribe them. The note beside each drug names the country and the use that was approved.
Does Submitted mean a drug will be approved?
No. Submitted means a regulator has accepted a marketing application and begun its review. The FDA says its review team has 6 to 10 months to decide once an application is complete, and the answer can be no.3 Nine of the 10 submitted drugs on this list are under review in China, so even an approval there would not make them available in the United States.
How can I find a clinical trial for a new weight loss drug?
Select any drug name in the tracker. It opens a ClinicalTrials.gov search for that drug, and each study record shows who can join, where the study runs and whether it is recruiting.1 Trials have strict entry rules, and you may be given a placebo. Talk with your own doctor before you enroll, especially if you take other medication.
How current is the tracker, and how was it checked?
Every row was checked on November 19, 2026 against a primary source: a company pipeline page, press release or filing, a regulator’s database, or a trial registry. Each note links to the document we read. A status can change the next day, so treat the date above the table as the limit of what we know, and confirm anything important with the source.
Sources
- National Library of Medicine. ClinicalTrials.gov. Trial records read on November 19, 2026. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. The Drug Development Process, Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- U.S. Food and Drug Administration. The Drug Development Process, Step 4: FDA Drug Review. https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
- U.S. Food and Drug Administration. Expanded Access. Content current as of October 22, 2026. https://www.fda.gov/news-events/public-health-focus/expanded-access
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Zepbound (tirzepatide) injection. Prescribing Information. Eli Lilly and Company. Revised 8/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Wegovy (semaglutide) injection and tablets. Prescribing Information. Novo Nordisk. Revised 6/2026. https://www.novo-pi.com/wegovy.pdf
- U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication, November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- Novo Nordisk. CagriSema REDEFINE 9 trial data presented at ObesityWeek 2026. Press release, November 14, 2026. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine-9-trial-obesityweek-2026.html
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. Press release, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Boehringer Ingelheim. Survodutide SYNCHRONIZE-CVOT trial results. Press release, November 9, 2026. https://www.globenewswire.com/fr/news-release/2026/11/09/3398586/0/en/boehringer-ingelheim-s-survodutide-is-the-first-glucagon-glp-1-dual-agonist-to-demonstrate-a-favorable-cardiovascular-safety-profile-in-global-phase-iii-synchronize-cvot-trial-alon.html
- U.S. Food and Drug Administration. Drugs@FDA: Wegovy tablets, NDA 218316. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
- U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Press announcement, April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
The source for each drug’s status is linked from its row in the table. This page is general information, not medical advice. Drugs described as investigational have not been approved and are not available from AM Rx.
Ask a provider about the GLP-1 options you can fill now
The health questionnaire takes a few minutes and is read by a licensed provider. Your first month of AM Rx membership is $39.

Care that does not wait on a drug still in trials
A licensed AM Rx provider reviews your health history online, usually within 1 to 2 business days, and tells you whether a GLP-1 medication you can fill now is a fit.
The AM Rx care team checks the medical content of this page against FDA prescribing information and published clinical trials. It is general health education and does not replace advice from your own provider.
AM Rx members, in their own words
One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
I started semaglutide at the recommendation of my AM Rx provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and AM Rx was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Since I started AM Rx, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Individual results may vary. These reviews describe the experience of individual AM Rx members and do not promise any result. Medication is prescribed only if a licensed provider considers it appropriate.
The GLP-1 medications AM Rx providers prescribe
Four brand-name medications and two compounded options. Which one you are offered depends on your health history and a licensed provider’s judgment, and our insurance coordinators file the prior authorization when a brand-name drug is prescribed.
Zepbound®
Weekly tirzepatide. FDA-approved for chronic weight management and for obstructive sleep apnea in adults with obesity.
Zepbound cost, coupons and side effects →Wegovy®
Semaglutide for chronic weight management, FDA-approved as a weekly injection and as a once-daily tablet.
Wegovy pill, price and side effects →Mounjaro®
Weekly tirzepatide with an FDA approval for type 2 diabetes. It shares its active ingredient with Zepbound.
Mounjaro doses and savings card →Ozempic®
Weekly semaglutide with an FDA approval for type 2 diabetes. Using it for weight loss is off-label.
Ozempic side effects and cost →Compounded semaglutide
$199 a month, or from $106 a month when you order a 3-month supply. Shipping is included. Not FDA-approved.
Semaglutide cost and dosing →Compounded tirzepatide
$329 a month, or from $216 a month when you order a 3-month supply. Shipping is included. Not FDA-approved.
Tirzepatide dosage and cost →A partner pharmacy prepares compounded medication for one patient’s prescription at a time. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. AM Rx membership costs $39 for the first month and $135 a month after that, and is charged separately from medication. Nothing is prescribed unless a licensed provider finds it appropriate.